Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current schizophrenia drugs: efficacy and side effects.

Michael Krebs1, Karolina Leopold, Axel Hinzpeter

  • 1Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Schumannstr. 20/21, D-10117 Berlin, Germany.

Expert Opinion on Pharmacotherapy
|May 26, 2006
PubMed
Summary

Second-generation antipsychotics improve schizophrenia treatment but cause side effects. Optimizing treatment requires personalized drug selection and better side-effect management for improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional Outcome Prediction in Young Adults With Mental Health Symptoms Using Machine Learning and Large Language Models: Longitudinal Observational Study.

JMIR mental health·2026
Same author

The renin-angiotensin system is activated by short-term, but repressed by long-term growth hormone excess.

European journal of endocrinology·2026
Same author

Cardiovascular effects of metyrapone treatment in patients with mild autonomous cortisol secretion: a secondary analysis.

The Journal of clinical endocrinology and metabolism·2026
Same author

Childhood maltreatment is linked to transdiagnostic age- and sex-specific cortical thinning and reduced amygdalar volume in young adults.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Heritability of the olfactory bulb and its associated brain network.

NeuroImage·2026
Same author

Initiation of aripiprazole once-monthly via a two‑injection start in adult patients diagnosed with schizophrenia: real-world experiences of healthcare professionals from five European countries.

Annals of general psychiatry·2026

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Second-generation antipsychotics (SGAs) are widely used for schizophrenia, offering improved tolerability and quality of life compared to older drugs.
  • SGAs have a reduced risk of extrapyramidal side effects and tardive dyskinesia.
  • Despite benefits, SGAs can cause significant adverse effects like weight gain, metabolic changes, and QTc-prolongation, leading to treatment discontinuation.

Purpose of the Study:

  • To discuss the challenges and opportunities in optimizing individualized treatment for schizophrenia using second-generation antipsychotics.
  • To highlight the need for strategies that enhance the efficacy and tolerability of current antipsychotic medications.
  • To explore methods for improving patient quality of life and treatment compliance.

Main Methods:

Related Experiment Videos

  • Review of current literature on second-generation antipsychotics for schizophrenia treatment.
  • Analysis of adverse effect profiles and their impact on patient adherence.
  • Discussion of potential strategies for personalized pharmacotherapy and integrated non-pharmacological interventions.

Main Results:

  • SGAs offer advantages in long-term treatment and tolerability for schizophrenia.
  • Adverse effects associated with SGAs are a major cause of treatment non-compliance.
  • Individualized treatment approaches are crucial for maximizing therapeutic benefits and patient well-being.

Conclusions:

  • Optimizing schizophrenia treatment necessitates increasing the efficacy of existing SGAs.
  • Identifying clinical or pharmacogenetic predictors can guide the selection of optimal drug therapies.
  • Improving side-effect management and integrating non-pharmacological interventions are key to enhancing patient quality of life and long-term outcomes.